## **BRISTOL-MYERS SQUIBB CO.**

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock



#### **Company Profile**

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

## Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets I	Liabilities and equity
Current assets	31,770,000,000		27,273,000,000		33,262,000,000	
Common stock capital		292,000,000		292,000,000		292,000,000
Fixed assets	63,389,000,000		69,547,000,000		76,052,000,000	
Equity capital of a company		29,485,000,000		31,118,000,000		36,006,000,000
Cash and cash equivalents	11,519,000,000		9,271,000,000		14,119,000,000	
Accrued liabilities		480,000,000		402,000,000		654,000,000
Other assets	-		-		-	
Current liabilities		22,262,000,000		21,890,000,000		21,868,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		43,412,000,000		43,812,000,000		51,440,000,000
Different income		-		-		-
Other liabilities		4,411,000,000		4,927,000,000		5,806,000,000
Total assets	95,159,000,000	95,159,000,000	96,820,000,000	96,820,000,000	109,314,000,000	109,314,000,000

#### **Balance notes**

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	34,100	34,300	32,200
Equity ratio	31.04%	32.20%	32.99%
Debt-equity ratio	222.14%	210.57%	203.09%

#### **Others**

	2023	2022	2021
Tax Expense Rate	4.74%	17.74%	13.39%

# **BRISTOL-MYERS SQUIBB CO.**

ISIN: US1101221083 WKN: 110122108 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	45,006,000,000	46,159,000,000	46,385,000,000
Net income	8,025,000,000	6,327,000,000	6,994,000,000
EBIT	8,502,274,500	8,146,659,000	8,721,400,500
Operating income before taxes	8,440,000,000	7,713,000,000	8,098,000,000
Cash Flow	13,860,000,000	13,066,000,000	16,207,000,000
Net interest income	-717,000,000	-1,061,000,000	-1,295,000,000
Research and development expenses	9,207,000,000	9,411,000,000	9,533,000,000
Income taxes	400,000,000	1,368,000,000	1,084,000,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	1,225,457	1,249,523	1,337,530

### **Board of Directors**

Members of Management Board		
Deepak Bhatt	Member of Board of Directors	
Julia Haller	Member of Board of Directors	
Karen Vousden	Member of Board of Directors	
Manuel Hidalgo Medina	Member of Board of Directors	
Derica Rice	Member of Board of Directors	
Paula Price	Member of Board of Directors	
Peter Arduini	Member of Board of Directors	
Phyllis Yale	Member of Board of Directors	
Theodore Samuels	Member of Board of Directors	
Chris Boerner	Chairman of Managing Board	
Adam Lenkowsky	Member of Executive Committee	
Amanda Poole	Member of Executive Committee	
Cari Gallman	Member of Executive Committee	
David Elkins	Member of Executive Committee	
Greg Meyers	Member of Executive Committee	
Karin Shanahan	Member of Executive Committee	
Kim Jablonski	Member of Executive Committee	
Lynelle B. Hoch	Member of Executive Committee	
Pamela Fisher	Member of Executive Committee	
Peter S. Paine III	Member of Executive Committee	
Robert Plenge	Member of Executive Committee	
Samit Hirawat	Member of Executive Committee	
Sandra Leung	Member of Executive Committee	